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Letters to the Editor
A clinical case of drug 
hypersensitivity syndrome with 
phenobarbital administration: 
drug-induced rash with 
eosinophilia and systemic 
symptoms or lupus-like sydrome? 
Sirs,
On April 26, 2005, an 84-year-old woman 
was admitted to our department for synco-
pe. She presented motor aphasia, nuchal ri-
gidity and right hemiparesis. The remaining 
clinical examination was normal. Brain CT 
scan evidenced subarachnoid haemorrhagic 
effusion at the superior cistern, cisterna 
laminae terminalis and subaracnoid spaces 
of the left parietal convexity. During the 
CT exam, she presented a short-term tonic 
clonic episode, which cleared up spontane-
ously. Electroencephalography showed dif-
fuse slowing of brain waves. She was treat-
ed with nimodipine i.v. and phenobarbital 
(100mg/day) by oral route: a gradual, clini-
cal improvement, conﬁrmed by brain CT 
scan, was evidenced. On May 9, she pre-
sented continuous, high fever, facial oede-
ma and generalized morbilliform eruption, 
with pruriginous papules and macules coa-
lescing into larger patches. Laboratory tests 
revealed anaemia (10.9 g/dl), eosinophilia 
(15.1 %), an increase of ESR (35mm/ﬁrst 
hour) and transaminases (SGOT 56 UI/
l, n.v.=5-40 ; SGPT 89 UI/l, n.v.=5-40). 
An abdomen echography showed mild 
hepatomegaly with homogeneous structure. 
A chest x-ray evidenced bilateral pleural 
effusion. Blood, urine, stool and sputum 
cultures, and the serological tests for hepa-
titis viruses, Epstein-Barr virus, human 
immunodeﬁciency virus, cytomegalovirus, 
mumps, rubella, measles, echovirus, cox-
sackievirus, parvovirus B19, HHV-6, her-
pes zoster, chlamydia, borrelia, toxoplasma, 
mycoplasma pneumoniae, mycobacterium 
tuberculosis and group A streptococcus 
were performed: they were all negative. 
On May 11, she presented pulmonary em-
bolism and was treated with heparin infu-
sion. Focalising on the administrated drugs, 
we noted that fever, rash, visceral involve-
ment, and eosinophilia developed about 12 
days after the start of phenobarbital treat-
ment. Suspecting a drug-induced systemic 
syndrome, we interrupted the drug. Further 
laboratory tests showed: antinuclear au-
toantibodies (ANAs) (ﬁne speckled nuclear 
pattern 1:160, nuclear dots 1:640), Ro/SS-
A and Ro/SS-B, screening-lupus anticoagu-
lant (LA), IgA and IgM aCL (respectively, 
12.1 APLU/ml, n.v.<10.0; 11.0 MPLU/ml, 
n.v.< 10.0) positive;  immunoglobulins, C3 
and C4, total B and T lymphocytes, CD4+ 
and CD8+ lymphocytes, anti-ds DNA, anti-
Sm and anti-histone antibodies in normal 
limits or negative. The patientʼs HLA hap-
lotype was the following: A2-A3/B51-B52/
BW4/CW4-CW6/DR8/DQ4. On May 14, 
methylprednisolone treatment (40 mg/day) 
was started. Fever decreased rapidly and 
the rash disappeared completely one month 
later. On June 22, she was discharged from 
hospital in good health and did not present 
any subsequent recurrence. Our patient 
satisﬁes the diagnostic criteria for Drug-in-
duced Rash with Eosinophilia and Systemic 
Symptoms (DRESS Syndrome), a severe, 
unexpected reaction to a medicine, starting 
one to eight weeks after taking the drug and 
affecting several organ systems contem-
poraneously (1). The pathogenesis is still 
unknown: Defects in drug metabolization, 
and/or a co-infection with HHV-6 (2) are 
the most quoted hypotheses. Phenobarbi-
tal can induce DRESS syndrome (3), not 
safely Drug-Induced Lupus Erythematosus 
(DILE) (4). Nevertheless, DILE (1) shares 
many clinical and laboratory ﬁndings with 
DRESS syndrome (5): a systemic involve-
ment is always present; the disease starts 
after using the culprit drug; the clinical im-
provement begins when the drug is discon-
tinued; serum immunological abnormalities 
are present. Moreover, DILE can be caused 
by anticonvulsants, except phenobarbital 
(6): But phenobarbital can induce ANAs 
positivity (7). At last, some immunologi-
cal changes were demonstrated in DRESS 
syndrome: immunoglobulins were normal 
or increased; complement normal or de-
creased; ANAs, ENAs and antiphospholipid 
antibodies present or not (8, 9). Therefore, 
we asked ourselves: Are DRESS syndrome 
and DILE really different disorders? Might 
be they different patterns of the same im-
munological-mediated systemic drug reac-
tion? How much might genetic assessment 
and/or environmental factors inﬂuence the 
phenotypic expression of the disorders? The 
question remains: HLA DR4 predisposes to 
DILE (5), while there are no data on HLA 
antigens in DRESS syndrome; HHV-6 can 
be implicated in the pathogenesis of DRESS 
syndrome (2) and perhaps of SLE (10). Our 
patient did not present HLA DR4 and was 
negative for HHV-6: May these conditions 
justify the development of DRESS syn-
drome rather then DILE? This clinical case 
offers itself as an occasion for debate. 
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